Neoadjuvant endocrine treatment (NET) is an established treatment option for selected postmenopausal women with large, hormone receptor-positive (HR+)/HER2-negative (HER2-) breast cancers, in particular for the luminal A subtype [1,2]. This evidence concerns the gene ERBB2 and breast cancer.